Feed NTRA
NT

Natera NTRA · NASDAQ

$393.44 -2.80% (-$11.35)

Market cap
$56.7B
Enterprise value
$55.9B
P/E
-
Forward P/E
-
PEG
-
P/S
20.9x
P/FCF
791.0x
EV/EBITDA
-
ROIC
-10.0%
Gross margin
65.3%
Net margin
-7.1%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
1.50
Free float
93.6%

About the company

Natera, Inc. (NTRA) is an American biotechnology company specializing in the development and production of non-invasive genetic tests. With advanced technologies in reproductive medicine, oncology, and transplantation, Natera provides accurate and reliable tests for prenatal screening, detection of tumor markers, and transplant monitoring. The company is known for its focus on innovation and the use of advanced bioinformatics tools, enabling it to deliver high-quality genetic testing. Natera also collaborates with medical institutions and research organizations to enhance diagnostic capabilities. Natera, Inc. (NTRA) shares could be suitable for investors looking for opportunities in the biotechnology sector with a focus on genetic testing and innovations in non-invasive diagnostics.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Steven Leonard Chapman

Employees

6,138

Headquarters

Austin

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.